# FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

> **NCT02398773** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 99 (estimated)

## Conditions studied

- HER2/Neu Negative
- Progesterone Receptor Negative
- Progesterone Receptor Positive
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** F-18 16 Alpha-Fluoroestradiol
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02398773
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-04
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398773, "FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02398773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*